Buchumschlag

The interferon-alpha revival in CML

Interferon-alpha (IFNα) was once the standard of frontline treatment for chronic myeloid leukemia (CML). Its pleiotropic mechanism of action in CML includes immune activation and specific targeting of CML stem cells. Early studies of IFNα in CML demonstrated that patients in chronic phase could atta...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Talpaz, Moshe (VerfasserIn) , Mercer, Jessica (VerfasserIn) , Hehlmann, Rüdiger (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: April 2015
In: Annals of hematology
Year: 2015, Jahrgang: 94, Pages: S195-S207
ISSN:1432-0584
DOI:10.1007/s00277-015-2326-y
Online-Zugang:Verlag, Volltext: http://dx.doi.org/10.1007/s00277-015-2326-y
Verlag, Volltext: https://link-springer-com.ezproxy.medma.uni-heidelberg.de/article/10.1007/s00277-015-2326-y
Volltext
Verfasserangaben:Moshe Talpaz, Jessica Mercer, Rüdiger Hehlmann

MARC

LEADER 00000caa a2200000 c 4500
001 1567996256
003 DE-627
005 20220814064620.0
007 cr uuu---uuuuu
008 180201s2015 xx |||||o 00| ||eng c
024 7 |a 10.1007/s00277-015-2326-y  |2 doi 
035 |a (DE-627)1567996256 
035 |a (DE-576)497996251 
035 |a (DE-599)BSZ497996251 
035 |a (OCoLC)1340986271 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Talpaz, Moshe  |e VerfasserIn  |0 (DE-588)1144903009  |0 (DE-627)1005031169  |0 (DE-576)49550372X  |4 aut 
245 1 4 |a The interferon-alpha revival in CML  |c Moshe Talpaz, Jessica Mercer, Rüdiger Hehlmann 
264 1 |c April 2015 
300 |a 13 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 01.02.2018 
520 |a Interferon-alpha (IFNα) was once the standard of frontline treatment for chronic myeloid leukemia (CML). Its pleiotropic mechanism of action in CML includes immune activation and specific targeting of CML stem cells. Early studies of IFNα in CML demonstrated that patients in chronic phase could attain extremely stable remissions, which correlated with long-term survival. Some patients even sustained their remission after discontinuing therapy, but the mechanism underlying this phenomenon is not well understood. Today, BCR-ABL tyrosine kinase inhibitors (TKIs), such as imatinib, induce remarkable responses in CML patients and have become the mainstay of CML therapy. Although TKIs target the pathogenic BCR-ABL protein in CML, they cannot fully eradicate CML stem cells. Some of the clinical trials testing IFNα plus imatinib combination therapy suggest that addition of IFNα increases the speed and rate of responses with imatinib therapy. However, the undesirable side effects of IFNα can make this therapy difficult to deliver, and the optimal therapeutic window for using IFNα in combination therapy is unknown. Further studies are needed to clarify the best niche for IFNα use in CML. 
700 1 |a Mercer, Jessica  |e VerfasserIn  |0 (DE-588)1151659975  |0 (DE-627)1012141640  |0 (DE-576)497996138  |4 aut 
700 1 |a Hehlmann, Rüdiger  |d 1941-  |e VerfasserIn  |0 (DE-588)1037003489  |0 (DE-627)751737879  |0 (DE-576)390939463  |4 aut 
773 0 8 |i Enthalten in  |t Annals of hematology  |d Berlin : Springer, 1991  |g 94(2015), Supplement 2, Seite S195-S207  |h Online-Ressource  |w (DE-627)253389852  |w (DE-600)1458429-3  |w (DE-576)072283157  |x 1432-0584  |7 nnas  |a The interferon-alpha revival in CML 
773 1 8 |g volume:94  |g year:2015  |g supplement:Supplement 2  |g pages:S195-S207  |g extent:13  |a The interferon-alpha revival in CML 
856 4 0 |u http://dx.doi.org/10.1007/s00277-015-2326-y  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://link-springer-com.ezproxy.medma.uni-heidelberg.de/article/10.1007/s00277-015-2326-y  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20180201 
993 |a Article 
994 |a 2015 
998 |g 1037003489  |a Hehlmann, Rüdiger  |m 1037003489:Hehlmann, Rüdiger  |d 60000  |e 60000PH1037003489  |k 0/60000/  |p 3  |y j 
999 |a KXP-PPN1567996256  |e 2994892987 
BIB |a Y 
SER |a journal 
JSO |a {"physDesc":[{"extent":"13 S."}],"language":["eng"],"id":{"doi":["10.1007/s00277-015-2326-y"],"eki":["1567996256"]},"recId":"1567996256","origin":[{"dateIssuedKey":"2015","dateIssuedDisp":"April 2015"}],"relHost":[{"titleAlt":[{"title":"Hematology"}],"disp":"The interferon-alpha revival in CMLAnnals of hematology","title":[{"title_sort":"Annals of hematology","subtitle":"organ of: Gesellschaft für Thrombose- und Hämostaseforschung, DGHO, Deutsche Gesellschaft für Hämatologie und Onkologie e.V., ÖGHO, Österreichische Gesellschaft für Hämatologie und Onkologie","title":"Annals of hematology"}],"id":{"zdb":["1458429-3"],"eki":["253389852"],"issn":["1432-0584"]},"recId":"253389852","physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"note":["Gesehen am 24.04.2025","Fortsetzung der Druck-Ausgabe","Ungezählte Beil. ab 80.2001: Supplement"],"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"publisher":"Springer","dateIssuedKey":"1991","dateIssuedDisp":"1991-","publisherPlace":"Berlin ; Heidelberg ; New York"}],"pubHistory":["62, 1 (Februrary 1991)-"],"part":{"volume":"94","extent":"13","pages":"S195-S207","text":"94(2015), Supplement 2, Seite S195-S207","year":"2015"}}],"note":["Gesehen am 01.02.2018"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"name":{"displayForm":["Moshe Talpaz, Jessica Mercer, Rüdiger Hehlmann"]},"person":[{"roleDisplay":"VerfasserIn","role":"aut","family":"Talpaz","given":"Moshe","display":"Talpaz, Moshe"},{"display":"Mercer, Jessica","given":"Jessica","family":"Mercer","roleDisplay":"VerfasserIn","role":"aut"},{"roleDisplay":"VerfasserIn","role":"aut","family":"Hehlmann","given":"Rüdiger","display":"Hehlmann, Rüdiger"}],"title":[{"title":"The interferon-alpha revival in CML","title_sort":"interferon-alpha revival in CML"}]} 
SRT |a TALPAZMOSHINTERFERON2015 

Ähnliche Einträge